

Edgar Filing: MEDICIS PHARMACEUTICAL CORP - Form 8-K

MEDICIS PHARMACEUTICAL CORP

Form 8-K

April 22, 2004

=====

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15 (d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): April 20, 2004

MEDICIS PHARMACEUTICAL CORPORATION  
(Exact Name of Registrant as Specified in Charter)

Delaware  
(State or Other  
Jurisdiction of Incorporation)

0-18443  
(Commission File Number)

52-1574808  
(IRS Employer  
Identification No.)

8125 North Hayden Road  
Scottsdale, Arizona  
(Address of Principal  
Executive Offices)

85258-2463  
(Zip Code)

Registrant's telephone number, including area code:

(602) 808-8800

N/A

-----  
(Former Name or Former Address, if Changed Since Last Report)

=====

Item 5. Other Events and Regulation FD Disclosure

On April 20, 2004, Medicis Pharmaceutical Corporation (the "Company") issued a press release announcing that it had entered into an asset purchase agreement, license agreement and securities purchase agreement with BioMarin Pharmaceutical, Inc.

Edgar Filing: MEDICIS PHARMACEUTICAL CORP - Form 8-K

99.1. A copy of the Company's press release is attached hereto as Exhibit

Item 7. Financial Statements and Exhibits

(a) Financial Statements of Business Acquired.

Not Applicable.

(b) Pro Forma Financial Information.

Not Applicable.

(c) Exhibits.

99.1 Copy of press release, dated April 20, 2004, issued by Medicis Pharmaceutical Corporation

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

MEDICIS PHARMACEUTICAL CORPORATION  
(Registrant)

Date: April 21, 2004

/s/ Mark A. Prygocki, Sr.

-----  
Name: Mark A. Prygocki, Sr.  
Title: Executive Vice President,  
Chief Financial Officer,  
Corporate Secretary and  
Treasurer

EXHIBIT INDEX

EXHIBIT NUMBER -----	DESCRIPTION -----
99.1	Copy of press release, dated April 20, 2004, issued by Medicis Pharmaceutical Corporation